OncoNano Closes Additional $23.7 Million in Second Tranche of Series A Financing, Bringing Total Series A Raise to $35.4 Million

Proceeds will be used to support new and ongoing cancer imaging clinical trials and to advance development of its pH-activated compound platform for cancer therapeutics and vaccines

SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc. today announced the completion of $23.7 million in a second tranche of Series A financing, bringing the total Series A round to $35.4 million. The round was arranged by Salem Partners, who also participated as a principal investor. Proceeds of the financing will fuel OncoNano’s cancer imaging clinical trials and support the expansion of its technology into candidates for therapeutic applications.

“Over the last year, OncoNano has made significant strides in the completion of a Phase 1 trial for our intraoperative cancer imaging agent, ONM-100, which saw a 100 percent imaging response in patients, as well as the expansion of the use of our pH sensitive micelle platform into exciting new areas such as therapeutics and cancer vaccines,” said Ravi Srinivasan, CEO of OncoNano Medicine. “The continued support of our distinguished investors and the addition of new investors into the OncoNano family will enable us to further our mission to change how cancer is detected and treated.”

ONM-100 is the first product in a platform based upon the company’s library of unique micelles that are ultra-sensitive to changes in pH. The intravenously administered imaging agent, which detects tumors and metastatic lymph nodes, is entering a Phase 2 clinical trial. The company announced earlier this year that the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application for ONM-100 and granted a Fast Track designation in response to a separate application. OncoNano’s micelle platform is also being used to develop therapeutics, including a T-cell activator that targets lymph nodes and dendritic cells to treat cancers.

“The combination of OncoNano’s experienced executive and scientific team coupled with the progress the company is making in expanding the platform across multiple imaging and therapeutic applications underscores the tremendous interest in the company from both existing and new investors,” said John Dyett, Co-Founder and Managing Director at Salem Partners, who also serves on OncoNano’s Board of Directors. “We have full confidence in the company’s potential to make a significant impact in the future of cancer care.”

About OncoNano Medicine

OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple and effective identifier of diseased tissue providing a foundation for the development of a broad range of highly targeted therapeutics and imaging agents. OncoNano is the first company to advance product candidates using pH as a biomarker for cancer immunotherapy, therapeutic use and intra-operative imaging based on its pH-sensitive micelle technology.

www.onconanomed.com

Contacts

MacDougall

Lauren Arnold, 781-235-3060

[email protected]